#Sweden #Lund #Hansa Biopharma #imlifidase #IDEFIRIX

Hansa Biopharma Sets PDUFA Date for Imlifidase

Hansa Biopharma AB, renowned for its innovative medical solutions, announced on March 4, 2026, that the FDA has officially assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026, for the Biologics License Application (BLA) of Imlifidase. This announcement signifies a significant step forward in the journey to provide transformative therapy options for patients in the U.S. suffering from severe sensitization which complicates kidney transplants.

The Urgent Need for Kidney Transplant Options

For many patients awaiting kidney transplantation, the option of receiving a compatible kidney donor is often fraught with obstacles. According to estimates, highly sensitized patients account for approximately 10-15% of the waiting list. These patients exhibit high levels of donor-specific antibodies (DSA) to human leukocyte antigens (HLA) which substantially reduces their chances of finding a suitable donor. The immunological barriers they face can lead to delayed transplants and a reliance on long-term dialysis proposals.

In light of these challenges, the anticipated approval of Imlifidase could transform clinical practice in transplantation, offering new hope for this underserved population. Renée Aguiar-Lucander, CEO of Hansa Biopharma, expressed optimism about reaching this milestone, stating, "With the PDUFA date now set, we are one step closer to potentially offering Imlifidase as a transformative therapy option for patients who today have very limited access to a life-changing kidney transplant."

Understanding Imlifidase

Imlifidase is currently conditionally approved in Europe, the UK, and other regions under the trade name IDEFIRIX® for desensitization treatments aimed at highly sensitized adult kidney transplant candidates. This pioneering therapy works by utilizing an antibody-cleaving enzyme that specifically targets and reduces immunoglobulin G (IgG) antibodies, facilitating a more accessible transplant process.

The efficacy of Imlifidase has been evaluated through multiple Phase 2 clinical trials, which reported favorable outcomes for patients undergoing transplantation after treatment. As per its track record, Imlifidase has shown a rapid onset of action, mitigating the activity of IgG antibodies within just hours of administration. This is especially crucial for highly sensitized individuals, who often face prolonged wait times—or even indefinite delays—due to compatibility issues.

Significance of Approval

The potential approval of Imlifidase marks a watershed moment for many patients grappling with the complexities of kidney transplantation. It reveals a potential path toward increased survival and quality of life for countless individuals suffering from end-stage renal disease (ESRD). As of now, approximately 170,000 people are on transplant waiting lists in the U.S. and Europe, further underscoring the urgent necessity for innovative therapies in this sector.

Hansa Biopharma is poised to impact not only U.S. patients but also to set a precedent in international transplantation standards. With the FDA review on the horizon, Hansa looks forward to working closely with the regulatory body during this critical phase. Such collaboration could lead to the new treatment being rolled out as a routine part of transplant protocols, thus providing vital support to patients who have previously been overlooked.

Conclusion

As we inch closer to December 19, 2026, all eyes will be on Hansa Biopharma and the outcome of the PDUFA review for Imlifidase. This development could well redefine the landscape of kidney transplantation and offer renewed hope to those in desperate need of viable treatment options. The biopharmaceutical company remains committed to advancing care for individuals with urgent health needs through groundbreaking research and innovative therapies.

For more details about Hansa Biopharma and Imlifidase, visit www.hansabiopharma.com.